摘要
医学科技创新是推动卫生健康领域新质生产力发展的核心要素.在健康中国战略的指引下,我国持续增加卫生健康领域的投入,积极促进新质生产力的发展,并推动医学科技创新水平的持续提升,取得了一系列具有国际影响力的原创性成果.然而,医学科技整体创新能力仍需进一步提升,尤其亟须解决医学科技成果转化不足的问题[1~3].
Proof of concept(PoC),a critical innovation practice for translating scientific breakthroughs into real-world applications,has been widely adopted in developed countries.It validates the feasibility of early-stage research and bridges the gapbetween academic discovery and commercial investment.In the medical field,PoC focuses on advancing the results ofbasic research,such as novel drugs,diagnostics,or therapeutic technologies,through preclinical evaluation and pilotclinical trials,thereby shortening the long and costly path to clinical adoption.This paper systematically examines theevolution of PoC frameworks and analyses global best practices in the medical sector,drawing insights from case studies inthe US,the European Union(EU),Germany,Singapore and Japan in order to provide a policy reference for the fundingstrategies of medical science and technology innovation in China.Over the past two decades,PoC initiatives in developed countries have generally proven to be instrumental inaccelerating the translation of medical innovations into clinical applications.Despite differences in organizationalstructures and funding mechanisms,international PoC frameworks share four common principles.First,local demandorientation prioritises region-specific health needs.For example,the National Science Foundation(US)promotes“jointapplications”between academia and industry,while the Japan Science and Technology Agency(Japan)promotes“industry-academia research teams”to align projects with domestic priorities.Second,multi-stakeholder funding schemesintegrate government,academia and the private sector.The European Research Council(EU)and the European InnovationCouncil(EIC,EU)rely on public funding,although they emphasise cross-border collaboration,while the US combinesfederal grants,university resources,corporate partnerships and philanthropy.Third,tiered funding mechanisms optimiseresource allocation by tailoring support to technology readiness levels(TRLs).The EIC categorizes grants into“Pathfinder”(TRL 1–4)and“Transition”(TRL 5–6)tracks.Fourth,staged funding strategies ensure continuity fromresearch to commercialization.S-Innovation(Japan)spans 7–10 years for full-cycle development,and the NationalInstitute of Health(US)provides progressive funding,starting with initial grants of$50,000 and scaling up to$200,000based on milestones.These common principles underscore the global blueprint for bridging the“valley of death”inmedical innovation.In China,despite emerging efforts such as Shanghai’s National Translational Medical Infrastructure and Capital MedicalUniversity’s Clinical Basic Research Platforms,challenges remain in terms of fragmented funding,limited industryparticipation and underdeveloped validation pipelines.To address these gaps,this study proposes actionable suggestions:(1)expanding government grants for TRL-based pilot projects(e.g.,drug prototype validation);(2)incentivising corporateparticipation through tax breaks or co-funding models;(3)establishing multi-PI grant mechanisms to foster clinicianscientistpartnerships;and(4)adopting international peer review standards to prioritise high-impact medical needs.Byintegrating these strategies,China can strengthen its PoC ecosystem,translate its vast basic research output into clinicallyviable solutions,and advance healthcare innovation globally.
作者
姚刚
王斐
朱元贵
孙瑞娟
Gang Yao;Fei Wang;Yuangui Zhu;Ruijuan Sun(Department of Health Sciences,National Natural Science Foundation of China,Beijing 100085,China)
出处
《科学通报》
北大核心
2025年第13期1856-1863,共8页
Chinese Science Bulletin
关键词
资助机制
医学科技创新
国际概念验证计划
proof of concept
medical research
technology innovation
funding strategy
